Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, China.
Department of Urology, First Hospital of Shanxi Medical University, Taiyuan, China.
Medicine (Baltimore). 2024 Jan 19;103(3):e36950. doi: 10.1097/MD.0000000000036950.
We found the G132R heterozygous mutation of thyroid stimulating hormone receptor (TSHR) gene in a patient with recurrent hypokalemia. Because the patient had a medical history of hyperthyroidism, the mutation was suspected to be related to hyperthyroidism at first. Subsequently, the expression and function studies in vitro were conducted.
Wide-type TSHR and mutant TSHR (mutTSHR) were constructed in the phage vector and pEGFP-C1 vector. After transfection, the samples were collected for detection of mRNA level, protein expression, cell activity and cAMP content.
Compared with the wild-type TSHR, the mRNA level of the mutTSHR was not significantly different. But the protein expression, cell activity and cAMP content of the mutTSHR were significantly lower. So this indicated that the G132R mutation is a loss-of-function mutation.
We identified the G132R monoallelic heterozygous mutation of TSHR gene in a patient with hyperthyroidism. Based on disease history of the patient, we speculated that the heterozygous mutation did not cause thyroid dysplasia or hypothyroidism for her. Our study enriched experiment content in vitro studies and clinical phenotype about the G132R mutation in TSHR gene.
我们在一名反复低钾血症患者中发现促甲状腺激素受体(TSHR)基因的 G132R 杂合突变。由于患者有甲亢病史,最初怀疑该突变与甲亢有关。随后,我们进行了体外表达和功能研究。
在噬菌体载体和 pEGFP-C1 载体中构建野生型 TSHR 和突变型 TSHR(mutTSHR)。转染后,收集样本检测 mRNA 水平、蛋白表达、细胞活性和 cAMP 含量。
与野生型 TSHR 相比,mutTSHR 的 mRNA 水平无明显差异。但 mutTSHR 的蛋白表达、细胞活性和 cAMP 含量明显降低。这表明该 G132R 突变是一种失活突变。
我们在一名甲亢患者中鉴定出 TSHR 基因的 G132R 单等位基因杂合突变。基于患者的病史,我们推测该杂合突变并未导致其甲状腺发育不良或甲状腺功能减退。我们的研究丰富了 TSHR 基因 G132R 突变的体外实验内容和临床表型。